therapeutic options available for the treatment of type 2 diabetes?
Patients with type 2 diabetes have relative deficiency of both insulin and amylin. Several oral agents have been approved for use in type 2 diabetes. These agents typically increase insulin secretion (i.e., sulfonylureas, GLP-1 analogues, DPP-4 inhibitors), improve insulin sensitivity at target tissues (i.e., thiazolidinediones, biguanides,) or decrease the absorption of glucose (i.e., alpha glucosidase inhibitors). The mechanism of action and side effects of available noninsulin antidiabetic agents are described Table 65-1 . Insulin can also be prescribed alone or in combination with these agents. Long (i.e., glargine, detemir), intermediate (i.e., NPH) and short (i.e., lispro, aspart, glulisine, regular) acting insulins are available on the market.